Citius Oncology, Inc. (CTOR)Healthcare | Drug Manufacturers - Specialty & Generic | Cranford, United States | NasdaqCM
0.70 USD
+0.00
(0.556%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.69 -0.01 (-0.015%) ⇩ (July 13, 2026, 5:27 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:54 a.m. EDT
The immediate outlook is severely clouded by a collapsing price trend and deteriorating financial health. Over the last two years, the stock has lost over 73% of its value, driven by a catastrophic 75% drop in the most recent fiscal year. While the company is making headlines regarding commercial expansion of its cancer drug LYMPHIR and securing capital, these operational milestones cannot mask the reality that the market has priced out the business due to massive losses, a debt-to-equity ratio exceeding 10x, and a current ratio of just 0.5 indicating imminent liquidity stress. The recent price action shows a volatile but generally downward drift, failing to build any meaningful momentum. Without a clear path to profitability and with a balance sheet that appears fragile relative to its obligations, there is no compelling case for a near-term bounce or a long-term hold. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067169 |
| AutoARIMA | 0.133685 |
| AutoETS | 0.133685 |
| MSTL | 0.141037 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.700 |
| Excess Kurtosis | -0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.775 |
| Revenue per Share | 0.067 |
| Market Cap | 65,533,152 |
| Beta | 3.48 |
| Website | https://citiusonc.com/overview/default.aspx |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.64381444 |
| Address1 | 11 Commerce Drive |
| Address2 | First Floor |
| All Time High | 49.0 |
| All Time Low | 0.491 |
| Ask | 0.91 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 55,990 |
| Average Daily Volume3 Month | 83,713 |
| Average Volume | 83,713 |
| Average Volume10Days | 55,990 |
| Beta | 3.477 |
| Bid | 0.4837 |
| Bid Size | 2 |
| Book Value | 0.379 |
| City | Cranford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7048 |
| Current Ratio | 0.5 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.7056 |
| Day Low | 0.69 |
| Debt To Equity | 10.775 |
| Display Name | Citius Oncology |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 11.887 |
| Enterprise Value | 66,700,628 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.78674 |
| Fifty Day Average Change | -0.081939995 |
| Fifty Day Average Change Percent | -0.1041513 |
| Fifty Two Week Change Percent | -64.38145 |
| Fifty Two Week High | 2.84 |
| Fifty Two Week High Change | -2.1352 |
| Fifty Two Week High Change Percent | -0.751831 |
| Fifty Two Week Low | 0.491 |
| Fifty Two Week Low Change | 0.21380001 |
| Fifty Two Week Low Change Percent | 0.43543792 |
| Fifty Two Week Range | 0.491 - 2.84 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,670,509,800,000 |
| Float Shares | 17,721,288 |
| Free Cashflow | -23,616,774 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.80074996 |
| Gross Profits | 4,493,323 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.77511 |
| Held Percent Institutions | 0.15323 |
| Implied Shares Outstanding | 92,981,204 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc. |
| Long Name | Citius Oncology, Inc. |
| Market | us_market |
| Market Cap | 65,533,152 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1859892474 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -42,510,376 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 65,170,525 |
| Number Of Analyst Opinions | 1 |
| Open | 0.691 |
| Operating Cashflow | -16,678,610 |
| Operating Margins | -17.16166 |
| Payout Ratio | 0.0 |
| Phone | 908 967 6677 |
| Post Market Change | -0.014800012 |
| Post Market Change Percent | -2.099888 |
| Post Market Price | 0.69 |
| Post Market Time | 1,783,978,074 |
| Previous Close | 0.7009 |
| Price Hint | 4 |
| Price To Book | 1.8596306 |
| Price To Sales Trailing12 Months | 11.6785555 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.063 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00389999 |
| Regular Market Change Percent | 0.556426 |
| Regular Market Day High | 0.7056 |
| Regular Market Day Low | 0.69 |
| Regular Market Day Range | 0.69 - 0.7056 |
| Regular Market Open | 0.691 |
| Regular Market Previous Close | 0.7009 |
| Regular Market Price | 0.7048 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 22,578 |
| Return On Assets | -0.28314 |
| Return On Equity | -1.1989701 |
| Revenue Per Share | 0.067 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 92,981,204 |
| Shares Percent Shares Out | 0.0049 |
| Shares Short | 453,353 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 631,733 |
| Short Name | Citius Oncology, Inc. |
| Short Percent Of Float | 0.027 |
| Short Ratio | 7.49 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTOR |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 2,632,634 |
| Total Cash Per Share | 0.028 |
| Total Debt | 3,800,111 |
| Total Revenue | 5,611,409 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.09457 |
| Two Hundred Day Average Change | -0.38977003 |
| Two Hundred Day Average Change Percent | -0.35609418 |
| Type Disp | Equity |
| Volume | 22,578 |
| Website | https://citiusonc.com/overview/default.aspx |
| Zip | 7,016 |